This program does not treat, reverse, or cure autism.
Autism is a neurodevelopmental difference, not a disease with a cure — and many autistic people do not regard it as something to be treated at all. What this program addresses is far narrower: the neuroinflammation and immune dysregulation documented in a subset of children with ASD, using umbilical-cord MSC protocols as an investigational adjunct to — never a substitute for — established behavioral, developmental, and medical care.
The route is a short, monitored IV infusion, dosed by body weight, delivered during a three-to-five-day stay with structured follow-up at 30, 60, and 90 days.
Stem cell therapy for ASD is an early-stage, investigational treatment, not an approved or established one. TrueCell does not claim to treat, reverse, or cure autism, and no outcome is guaranteed. The strongest controlled evidence to date did not show a group-level benefit. All treatment decisions are made by a board-certified physician after a thorough individual evaluation, and results vary by patient.
What the program actually is.
Three parts: an honest evaluation, a personalized protocol, and structured follow-up. The consult exists partly to talk families out of treatment when it is not the right call — and we do that regularly.
Physician evaluation & candidacy screening
A board-certified physician reviews the formal ASD diagnosis, developmental history, current therapy plan, medical status, and medications. Baseline standardized parent- and clinician-rated scales are documented so any change can be tracked honestly, not by impression. We ask that the treating pediatrician or neurologist is aware and, ideally, supportive.
Complimentary · No obligationThe protocol: UC‑MSCs & exosomes
Wharton's jelly umbilical-cord-derived mesenchymal stem cells with exosomes, chosen for their immunomodulatory profile. The primary route is a monitored IV infusion; in select cases intrathecal delivery may be recommended by the physician. Dosage is personalized by body weight, age, severity, and history, with pediatric protocols carefully adjusted for safety and tolerability.
Weight-dosed · ISO-certified GMP labFamily-centered logistics & aftercare
A 3-to-5-day stay: arrival, evaluation, one or two procedure sessions, and recovery observation before departure — the infusion itself is short and calm, with a parent present throughout and pediatric-appropriate monitoring. Remote follow-up at 30, 60, and 90 days, with progress tracked through standardized assessments shared with families.
3–5 day stay · 30/60/90-day follow-upDosing is set by weight, and evaluation comes first.
No outcome statistics here, because we will not invent them. These are the facts of how the program is run.
Weight-dosed
Dosage is calculated from body weight, age, severity, and history — never a one-size package. Pediatric protocols are adjusted for safety and tolerability.
Evaluation first
Candidacy screening precedes any scheduling. If a physician concludes regenerative therapy is not the right answer for your child, that is what you will be told.
ISO‑certified
GMP laboratory. Viability, sterility, and identity are tested and documented before every application.
What researchers hypothesize the cells do.
This is a hypothesis under clinical study, not an established mechanism of benefit. Tap a step to follow it.
The family's journey.
Every stage is measured against the documented baseline taken at evaluation, not against impression.
Before travel
Evaluation & candidacy
Records review, virtual pre-consultation, and baseline standardized scales. If it is not the right call for your child, we say so here — before anyone books a flight.
Treatment stay
3 to 5 days on site
Arrival, in-person evaluation, one or two procedure sessions with a parent present throughout, and recovery observation before departure.
Days 30 · 60 · 90
Remote follow-up
Structured check-ins with progress tracked through standardized assessments shared with families — not anecdotes.
Beyond 90 days
A candid decision point
Results are compared honestly against the baseline. If there is no measurable benefit, we say so — and do not recommend chasing it with more infusions.
The evidence, honestly.
Three anchor findings from the peer-reviewed literature — including the null result. We will not cherry-pick.
Phase I
Duke's open-label safety trial: autologous cord-blood infusions were safe and feasible in young children with ASD, with parent-rated behavioral gains over six months.
Dawson G, et al. Stem Cells Transl Med, 2017.
RCT
The rigorous follow-up: Duke's randomized, placebo-controlled trial did not meet its primary social-communication endpoint across the whole group. A prespecified subgroup signal is hypothesis-generating, not proof.
Dawson G, et al. J Pediatr, 2020.
Safety
Updated systematic review and meta-analysis: intravascular MSC administration continues to appear safe, with adverse events typically mild, transient, and self-limited.
Thompson M, et al. EClinicalMedicine, 2020.
Read these limitations before anything else on this page. The evidence for cell therapy in autism is early-stage; efficacy signals have been inconsistent — some studies positive, the most rigorous ones largely negative — and the strongest controlled trial did not show a group-level benefit. Results vary widely between children, many will show no measurable change, and no outcome of any kind is guaranteed. This is not a cure, it does not "recover" a child from autism, and it is never a substitute for evidence-based behavioral, developmental, educational, and medical care, all of which should continue. Cell therapy is not FDA-approved for this indication; any protocol at TrueCell is provided as investigational care under Mexican regulatory authority (COFEPRIS), only after individual review by a board-certified physician, and families should be financially and emotionally prepared for the possibility of no benefit.
